Lb Pharmaceuticals (LBRX) Share-based Compensation (2024 - 2026)

Lb Pharmaceuticals' Share-based Compensation history runs 3 years deep, the most recent figure standing at $2.6 million for Q1 2026.

• In Q1 2026, Share-based Compensation rose 304.73% year-over-year to $2.6 million; the TTM figure through Mar 2026 stood at $5.7 million (changed N/A YoY), while the FY2025 annual figure was $4.2 million, up 5802.82% from the prior year.
• Share-based Compensation was $2.6 million for Q1 2026 at Lb Pharmaceuticals, up from $2.3 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $2.6 million in Q1 2026 to a low of $1000.0 in Q3 2024.
• Historically, Share-based Compensation has averaged $1.1 million across 3 years, with a median of $634000.0 in 2025.
• The sharpest annual moves came in 2025 and 2026: Share-based Compensation surged 11200.0% in 2025, then jumped 304.73% in 2026.
• A 3-year view of Share-based Compensation shows it stood at $1000.0 in 2024, then jumped by 234000.0% to $2.3 million in 2025, then advanced by 9.61% to $2.6 million in 2026.
• The last three Share-based Compensation figures came in at $2.6 million (Q1 2026), $2.3 million (Q4 2025), and $113000.0 (Q3 2025), per Business Quant data.